Yijing Capital is an investment company focuses on the medical and health-care sector.
Business Model:
Revenue: $0
Employees: 0-0
Address:
City:
State:
Zip:
Country:
Yijing Capital is an investment company focuses on the medical and health-care sector. Shanghai Yijing Investment Co. Ltd. was founded in 2015 as a sister company of Yizhou Group, which is among China’s Top 500 companies and has accumulated decades of experience in multiple industries. Yijing owns multiple investment platforms, undertaking equity investment with both self-owned and externally sourced funds. Yijing is positioned as a professional investment company with global footprint. The Yijing core team is equipped with years of operational and managerial expertise both at home and abroad. They mainly invest in industries with high growth potential. Currently, they have completed a dozen of investment projects domestically and internationally, covering sectors including smart manufacturing, medical and health-care, AI, new retail, education and new energy. Their investment will focus more on the medical and health-care sector, and also smart manufacturing. Most companies they have invested in are growing robustly and some have gone public, and they also have exited some companies with robust return.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
11/2020 | Zhiketong Technology | Series D | 50M |
2/2023 | NowYonMedical | Venture Round | - |
11/2018 | Shanutec | Series B | 7.2M |
3/2021 | Biren Technology | Series B | - |
10/2021 | Natural Melody | Series B | 31.3M |
10/2021 | Walnut Computer Technology | Series A | - |
6/2020 | eTheRNA immunotherapies | Series B | 0 |
11/2021 | Xgene Pharmaceutical | Series C | 0 |
3/2022 | CytoNiche | Series B | 0 |
3/2021 | Keythera Pharmaceuticals | Series A | 15.4M |
12/2020 | Raynovent | Series B | 42.8M |
11/2019 | independence Day | Series B | 2.9M |
1/2021 | Oricell Therapeutics | Series A | 0 |
3/2018 | Veritas Genetics | Venture Round | 4.6M |
9/2021 | Immunophage Biotech | Series A | - |
10/2019 | Yidebang | Series B | 14.1M |
1/2022 | Bivision | Seed Round | - |
3/2021 | Artivila Therapeutics | Seed Round | 22.8M |
5/2019 | EO Company | Series C | 11.6M |
4/2018 | EO Company | Series B | 10.2M |
1/2022 | InnoStar Semiconductor | Series A | - |
5/2021 | Kangpu Biopharmaceuticals, Ltd. | Series B | 0 |
10/2020 | Leto Laboratories | Series B | 14.9M |
7/2022 | Zhongguancun Shuimu Medical | Series A | 14.8M |
4/2021 | Tasogare | Series B | 41.1M |
10/2021 | ChosenMed | Series C | - |
11/2017 | EO Company | Series B | - |
4/2022 | Leisen Electronic Technology | Venture Round | - |
7/2022 | Zhongguancun Shuimu Medical | Series A | 0 |
4/2022 | Leisen Electronic Technology | Venture Round | - |
3/2022 | CytoNiche | Series B | 0 |
1/2022 | InnoStar Semiconductor | Series A | - |
11/2021 | Xgene Pharmaceutical | Series C | 0 |
10/2021 | Natural Melody | Series B | 0 |
10/2021 | Walnut Computer Technology | Series A | - |
10/2021 | ChosenMed | Series C | - |
9/2021 | Immunophage Biotech | Series A | - |
5/2021 | Kangpu Biopharmaceuticals, Ltd. | Series B | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|